The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review

por Wharton, Sean, Kamran, Elham, Muqeem, Mahnoor, Khan, Amina, Christensen, Rebecca A. G.
Publicado 2019

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery

por Wharton, Sean, Kuk, Jennifer L., Luszczynski, Magdalena, Kamran, Elham, Christensen, Rebecca A. G.
Publicado 2019

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial

por Wharton, Sean, Yin, Peter, Burrows, Melonie, Gould, Errol, Blavignac, Jessica, Christensen, Rebecca A. G., Kamran, Elham, Camacho, Fernando, Barakat, Maxime
Publicado 2021

Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program

por Wharton, Sean, Haase, Christiane L, Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca AG
Publicado 2020

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

por Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.
Publicado 2020